For Immediate Release: December 9, 2014

Minimus Spine Announces First Cases with Triojection® System

Minimus Spine reports that its Triojection® System was successfully used for the first time to treat patients. These cases were performed by surgeon advisor Dr. Josip Bunic of Florence, Italy and also Dr. Luca Coro and Dr. Luca Rigobello of Padua, Italy. Triojection® is intended to treat patients suffering from leg pain associated with a lumbar disc herniation. It is a novel percutaneous procedure involving the controlled delivery of ozone gas to a herniated disc. Patients were given a local anesthetic and the procedures each took about 15 minutes to perform.

“Although I have been using the ozone for some 20 years, the Triojection System takes ozone delivery to a herniated disc to a new level. Triojection gives a much higher level of confidence that the procedure minimizes the infection risk and ensures that a consistent concentration is administered to the disc. The initial follow-up on the first four patients shows early results to be very good. Significant leg pain improvement was achieved with VAS values dropping from 8-10 on pre-op evaluation to as low as 0-2 within a week of the procedure.”

Josip Bunic, MD
Neurosurgeon in Florence Italy

“Triojection® is uniquely positioned to provide significant relief to patients suffering from leg pain caused by a disc herniation- with a single injection. This treatment can be done at a significantly lower cost to the healthcare system and will allow many patients to avoid surgery.” said David Hooper, Ph.D., Minimus Spine’s President and Chief Executive Officer. “Minimus Spine will now move forward with plans for a multicenter, randomized, post-market study in Europe. That study is designed to compare the outcomes of Triojection to surgical discectomy. We will be looking to these results to provide the basis for discussions related to market adoption, reimbursement and the U.S. regulatory pathway. While we have had significant interest from distributors around the world, we are prioritizing this clinical study as our key value driver next year,” added Dr. Hooper.

About Minimus Spine: Established in 2006, Minimus Spine is a privately held medical device company dedicated to developing its ozone technology for medical applications. The company is focused on the treatment of spinal disorders related to herniated discs. Minimus Spine is headquartered in Austin, TX. For more information on Minimus Spine, please visit http://www.minimusspine.com or email info@minimusspine.com.